Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 9Phase 1 6Phase 1/2 3Phase NA 2Phase 2/3 2Phase 4 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × taxane × Clear all
NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Peregrine Pharmaceuticals

Phase 2/3 Withdrawn
Breast

Breast Neoplasms

NCT01641939 2017-05-12

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Hoffmann-La Roche

Phase 2/3 Terminated
415 enrolled 25 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡